STAA - Earnings announcements

Net Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $

Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast Date: Tuesday, March 3, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd Topics on the c

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended September 26, 2025. Third Quarter 2025 Financial Overview Net sales of $94.7 million up 6.9% Y/Y Net sales included $25.9 million related to the previously disclosed December 2024 ICL shipment that was subject to extended payment terms, and which was paid in full during the third quarter 2025 pursuant to such payment terms (the "December China Shipment") Net sales excluding China of $38.9 million up 7.7% Y/Y Gross margin at 82.2% vs. 77.3% year ago due to the timing of the reco

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to the decrease in sales volume, but up from 65.8% in Q1 of this year Net loss of $(16.8) million or $(0.34) per share, down from net income of $7.4 million or $0.15 per share year ago, but up from a net loss of $(54.2) million

STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today announced the companies have entered into a d

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Date: Wednesday, August 6, 2025 Time: 4:30 p.m. ET Location: https://registrations.events/direct/IDX8578398 The live webcast, including an option to pre-register, can be accessed at the preceding link o

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. "Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and our ability to return to sustainable, profitable growth," said Stephen C. Farrell, Chief Executive Officer of STAAR Surgical. "With a strong balance sheet, no debt, and clear progress in our cost optimization and strategic priorities, we

China ICL Procedure Trends Improving Tariff Mitigation Activities Implemented Cost Controls and Restructuring Initiated to Reduce SG&A Run Rate Earnings Call and Webcast Today at 5:15 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin at 65.8% vs. 78.9% year ago due

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2025 Financial Results Webcast Date: Wednesday, May 7, 2025 Time: 5:15 p.m. ET Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=VN5Skdjp The live webcast, including an option to pre-register, can be accessed at the

Net Sales of $313.9 Million and ICL Sales of $312.5 Million for Fiscal 2024 Impacted by Weak China Macroeconomic Conditions ICL Sales Ex. China Up 17% in Fourth Quarter and 13% in Fiscal 2024 Introduces Outlook for Fiscal 2025 Earnings Conference Call and Webcast Today at 5:00 p.m. Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended December 27, 2024. The Company moved up its earnings announcement and will hold a conference call and webcast today at 5:00 p.m. Eastern to discuss its financial results, oper

STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended December 27, 2024, on or about Wednesday, February 19 after the market close. "Our industry-leading EVO ICL technology and market-building initiatives supported our ability to achieve double-digit year-over-year ICL sales growth globally in fiscal 2024, with the exception of China," said Tom Frinzi, Chair of the Board and CEO of STAAR Surgical. "The pervasive and well-documented economic conditions and lower levels of consumer confidenc

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB STAAR will also host an earnings webcast on Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and op

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024 Financial Results Webcast Date: Wednesday, August 7, 2024 Time: 4:15 p.m. ET / 1:15 p.m. PT Location: https://staar-surgical-2q24-earnings.open-exchange.net/ STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. The

EVO ICL™ Continues to Outpace Refractive Industry Growth Record Quarterly U.S. Sales and Multiple Strategic Agreements Secured Reiterates Fiscal 2024 Net Sales Outlook and Increases Adjusted EBITDA STAAR Surgical Company (NASDAQ:K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024. First Quarter 2024 Overview Net sales up 5% to $77.4 million and up 7% in constant currency ICL sales up 9% and units up 2% Gross margin at 78.9% vs. 78.3% year ago Net loss of $3.3 million or $0.07 loss per share vs. net

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close. STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants. No access code is required. The live webcast can be accessed from the

Generates Double-Digit Sales Growth and Continuing Profitability ICL Sales Up 22% in Fourth Quarter and 18% in Fiscal 2023 Affirms Sales Outlook for Fiscal 2024 STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the fourth quarter and fiscal year ended December 29, 2023. Fourth Quarter 2023 Overview Net sales up 19% to $76.3 million in the fourth quarter ICL sales up 22% to $74.6 million and ICL units up 19% Gross margin at 79.6% vs. 77.7% year ago Net income of $7.8 million vs. $6.8 million year ago

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress. To access the conference call please dial 877-270-2148 for domestic participants and 412-902-6510 for international participants. No access code is required. The live webcast can be ac

Net Sales of $80.3 Million; ICL Sales of $81.1 Million Up 13% Y/Y 23rd Consecutive Quarter of Double-Digit ICL Sales Growth1 STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 29, 2023. Third Quarter 2023 Overview Net Sales of $80.3 Million Up 6% Y/Y includes a $0.8 Million sales reduction related to Other Products ICL Sales of $81.1 Million Up 13% Y/Y ICL Units Up 14% Y/Y Gross Margin at 79.2% vs. 79.5% in the Prior Year Quarter Net Income of $0.10 per Share vs. $0.21 per

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the third quarter ended September 29, 2023 on Wednesday, November 1, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, November 1 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 03857916), please dial 888-259-6580 for domestic participants and 206-962-3782 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at

Record ICL Sales of $93.1 Million Up 19% Y/Y STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency ICL Units Up 21% Y/Y Gross Margin at 76.6% vs. 78.8% in the Prior Year Quarter Net Income of $0.12 per Share vs. $0.26 per Share in the Prior Year Quarter Cash, Cash Equivalents and Investments Available for Sale Ended the Qu

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 99981426), please dial 888-259-6580 for domestic participants and 206-962-3782 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staa

Q1 2023 Net Sales of $73.5 Million; ICL Sales of $70.6 Million Up 20% Y/Y Fiscal 2023 Net Sales Outlook Raised to $348 Million; ICL Sales to $345 Million Up 28% Y/Y STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Overview Net Sales of $73.5 Million Up 16% and Constant Currency Net Sales of $75.5 Million Up 20% Y/Y ICL Sales of $70.6 Million Up 20% and Constant Currency ICL Sales of $72.4 Million Up 23% Y/Y ICL Units Up 20% Y/Y Gross Margin at 78.3% vs. 77.9% in the Prior Year Quarter Net Income of $0.05 p

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the first quarter ended March 31, 2023 on Wednesday, May 3, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, May 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 835957), please dial 833-470-1428 for domestic participants and 404-975-4839 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com. A

ICL Unit Growth Up 33% Y/Y in Fiscal 2022 STAAR Reaffirms Outlook for Strong Trajectory of Growth in 2023 STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today reported financial results for the fourth quarter and fiscal year ended December 30, 2022. Fourth Quarter 2022 Overview Net Sales of $64.0 Million Up 9% and Constant Currency Net Sales of $67.9 Million Up 15% from Prior Year Quarter ICL Sales of $61.2 Million Up 15% and Constant Currency ICL Sales of $64.3 Million Up 21% from Prior Year Quarter ICL Units Up 20% from the Prior Year Quarter Gross Margin at 77.7% vs. 76.3% in the Prior Year Quarter Net

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 30, 2022, on Tuesday, February 21, 2023 after the market close. STAAR will host a conference call and webcast on Tuesday, February 21 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 268065), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor r

ICL Units Up 40% Y/Y; Constant Currency Net Sales of $80.0 Million STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Overview Net Sales of $76.0 Million Up 30% and Constant Currency Net Sales of $80.0 Million Up 37% from the Prior Year Quarter ICL Sales of $72.0 Million Up 33% and Constant Currency ICL Sales of $75.2 Million Up 39% from the Prior Year Quarter ICL Units Up 40% from the Prior Year Quarter Gross Margin at 79.5% vs. 77.6% in the Prior Year Quarter Net Income of $0.21 p

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended September 30, 2022 on Wednesday, November 2, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, November 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 976076), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations sectio

ICL Units Up 42% Y/Y; Constant Currency Net Sales of $84.2 Million Announces Partnership with Joe Jonas to Raise EVO Global Awareness STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 1, 2022. Second Quarter 2022 Overview Record Net Sales of $81.1 Million Up 30% and Constant Currency Net Sales of $84.2 Million Up 35% from the Prior Year Quarter Record ICL Sales of $77.9 Million Up 32% and Constant Currency ICL Sales of $80.5 Million Up 36% from the Prior Year Quarter Record ICL Units Up 42% from the Prior Year Quarte

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, August 10 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 904311), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of th

EVO Visian® ICL Lenses Received FDA Approval and First Lenses Implanted STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the first quarter ended April 1, 2022. First Quarter 2022 Overview Record Net Sales of $63.2 Million Up 25% from the Prior Year Quarter ICL Sales of $58.7 Million Up 26% from the Prior Year Quarter Record ICL Units Up 29% from the Prior Year Quarter Gross Margin at 77.9% vs. 77.1% in the Prior Year Quarter Net Income of $0.19 per Share vs. Prior Year Quarter Net Income of $0.10 per Share Cash and Cash Equivalents Ended th

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, May 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 592913), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section of the STAAR

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Overview Net Sales of $59.0 Million Up 28% from the Prior Year Quarter ICL Sales of $53.0 Million Up 33% from the Prior Year Quarter ICL Units Up 36% from the Prior Year Quarter Gross Margin at 76.3% vs. 74.6% in the Prior Year Quarter Net Income of $0.10 per Share vs. Prior Year Quarter Net Income of $0.07 per Share Cash and Cash Equivalents Ended the Quarter at $199.7 Million Full Year 2021 Overview Record Ne

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the fourth quarter and fiscal year ended December 31, 2021 on Wednesday, February 23, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, February 23 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 142350), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investo

Third Quarter ICL Sales Up 31% Y/Y and Units Up 29% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $230 Million to $231 Million STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the third quarter ended October 1, 2021. Third Quarter 2021 Overview Quarterly Net Sales of $58.4 Million Up 24% from the Prior Year Quarter Quarterly ICL Sales of $54.2 Million Up 31% from the Prior Year Quarter Quarterly ICL Units Up 29% from the Prior Year Quarter Gross Margin at 77.6% vs. 74.1% in the Prior Year Quarter Net Income of $0.12 per Share vs

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the third quarter ended October 1, 2021 on Wednesday, November 3, 2021 after the market close. STAAR will host a conference call and webcast on Wednesday, November 3 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Access Code 249252), please dial 844-200-6205 for domestic participants and 929-526-1599 for international participants. The live webcast can be accessed from the investor relations section o

Second Quarter ICL Sales Up 93% Y/Y and Units Up 79% Y/Y Increases Full Year 2021 Net Sales Outlook to Range of $227 Million to $230 Million STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 2, 2021. Second Quarter 2021 Overview Record Quarterly Net Sales of $62.4 Million Up 77% from the Prior Year Quarter Record Quarterly ICL Sales of $59.2 Million Up 93% from the Prior Year Quarter Record Quarterly ICL Units, Up 79% from the Prior Year Quarter Gross Margin at 78.9% vs. 69.4% in the Prior Year Quarter Net Incom

STAAR Surgical Company (NASDAQ:STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 2, 2021 on Wednesday, August 4, 2021 after the market close. STAAR will host a conference call and webcast on Wednesday, August 4 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 6090849), please dial 866-209-9722 for domestic participants and 825-312-2235 for international participants. The live webcast can be accessed from the investor relations section of